Frontier Pharma - Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation
Frontier Pharma – Identifying and Commercializing first-in-class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and...
View full press release